Cover Image
市場調查報告書

Vaccibody AS 產品平台分析

Vaccibody AS - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321339
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Vaccibody AS 產品平台分析 Vaccibody AS - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 29 Pages
簡介

Vaccibody AS 是在挪威的製藥企業,著重開發對人、動物雙方有效的癌症及感染疾病的預防疫苗。該公司的產品候補的VB10.16是免疫醫藥品,進行對外陰部、子宮、頭部、頸部等的惡性腫瘤的治療藥開發。

本報告提供Vaccibody AS 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Vaccibody AS 基本資料

  • Vaccibody AS 概要
  • 主要資訊
  • 企業資料

Vaccibody AS :R&D概要

  • 主要的治療範圍

Vaccibody AS :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Vaccibody AS :開發中產品概況

  • 初期階段有的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Vaccibody AS :藥物簡介

  • herpes simplex vaccine
  • HIV vaccine
  • Influenza vaccine
  • Tuberculosis vaccine
  • Vaccine for B-Cell Lymphoma
  • Vaccine for Melanoma
  • Vaccine for Multiple Myeloma
  • Vaccine for Prostate Cancer
  • VB-1016
  • malaria vaccine

Vaccibody AS :開發平台分析

  • 各分子類型

Vaccibody AS :最新的開發平台資訊

Vaccibody AS :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07748CDB

Summary

Global Markets Direct's, 'Vaccibody AS - Product Pipeline Review - 2015', provides an overview of the Vaccibody AS's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vaccibody AS's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vaccibody AS including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vaccibody AS's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vaccibody AS's pipeline products

Reasons to buy

  • Evaluate Vaccibody AS's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vaccibody AS in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vaccibody AS's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vaccibody AS and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vaccibody AS
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vaccibody AS and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vaccibody AS Snapshot
    • Vaccibody AS Overview
    • Key Information
    • Key Facts
  • Vaccibody AS - Research and Development Overview
    • Key Therapeutic Areas
  • Vaccibody AS - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Vaccibody AS - Pipeline Products Glance
    • Vaccibody AS - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Vaccibody AS - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Vaccibody AS - Drug Profiles
    • VB-1016
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes simplex virus [type 2] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HIV vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tuberculosis vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for B-Cell Lymphoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Melanoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine for Prostate Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • malaria vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vaccibody AS - Pipeline Analysis
    • Vaccibody AS - Pipeline Products by Route of Administration
    • Vaccibody AS - Pipeline Products by Molecule Type
  • Vaccibody AS - Recent Pipeline Updates
  • Vaccibody AS - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vaccibody AS, Key Information
  • Vaccibody AS, Key Facts
  • Vaccibody AS - Pipeline by Indication, 2015
  • Vaccibody AS - Pipeline by Stage of Development, 2015
  • Vaccibody AS - Monotherapy Products in Pipeline, 2015
  • Vaccibody AS - Phase I, 2015
  • Vaccibody AS - Preclinical, 2015
  • Vaccibody AS - Discovery, 2015
  • Vaccibody AS - Pipeline by Route of Administration, 2015
  • Vaccibody AS - Pipeline by Molecule Type, 2015
  • Vaccibody AS - Recent Pipeline Updates, 2015

List of Figures

  • Vaccibody AS - Pipeline by Top 10 Indication, 2015
  • Vaccibody AS - Pipeline by Stage of Development, 2015
  • Vaccibody AS - Monotherapy Products in Pipeline, 2015
  • Vaccibody AS - Pipeline by Top 10 Molecule Type, 2015
Back to Top